Tue, December 19, 2023

Oren Livnat Maintained (CARA) at Strong Buy with Decreased Target to $2.5 on, Dec 19th, 2023

Oren Livnat of HC Wainwright & Co., Maintained "Cara Therapeutics, Inc." (CARA) at Strong Buy with Decreased Target from $7 to $2.5 on, Dec 19th, 2023.

Oren has made no other calls on CARA in the last 4 months.



There are 2 other peers that have a rating on CARA. Out of the 2 peers that are also analyzing CARA, 1 agrees with Oren's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • David Amsellem of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $1 on, Tuesday, November 14th, 2023


This is the rating of the analyst that currently disagrees with Oren


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $6 on, Monday, December 18th, 2023